Change in Platelet Lipid Metabolism and Procoagulant Phenotype Induced by Cardiopulmonary Bypass. Impact on Postoperative Inflammatory Response and Bleeding Complications During Cardiac Surgery.
Arterial blood sample: An arterial blood sample will be obtained at the beginning of the coronary angiography by using the arterial sheat in place, before administration of Heparin.
Arterial blood sample: An arterial blood sample will be obtained via the arterial line before anesthetic induction, 60 minutes after the beginning of cardiopulmonary bypass and 4 hours after the arrival in the intensive care unit
Study summary
The PLACARD research project aims to investigate the impact of CPB-induced platelet modifications during cardiac surgery on the post-operative inflammatory response and bleeding complications. Our objectives are to study the impact of CPB on the formation of procoagulant platelets, to assess changes in platelet lipid profile and bioenergetics before, during and after cardiac surgery, and to connect the ex-vivo observations to post-operative clinical and biological parameters of these patients during their stay in cardiovascular intensive care unit.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Adult patients (≥ 18 years old) suffering from coronary disease and/or severe valvular dysfunction (mitral or aortic) undergoing elective coronary angiography or cardiac surgery with cardiopulmonary bypass.
Exclusion Criteria:
* Uninterrupted preoperative dual antiplatelet therapy
* Active chronic inflammatory disease
* Recent chemotherapy or immunotherapy (\< 3 months)
* Active solid malignancy
* History of hematologic malignancy
* Hemophilia or other coagulopathy
* History of thrombocytopenia (\< 100,000 platelets/mm³)
* Recent administration of thrombopoietin receptor agonist or immunoglobulins
* History of thrombopathy, thrombocytosis, or myeloproliferative syndrome
* History of heparin-induced thrombocytopenia (HIT)
* Cirrhosis or hepatic fibrosis (with or without hypersplenism)
* History of splenectomy, regardless of initial indication
* History of systemic autoimmune disease (e.g., systemic lupus erythematosus, scleroderma, antiphospholipid syndrome, systemic vasculitis)
* Recent major surgery (\< 3 months)
* Severe renal insufficiency (eGFR ≤ 30 mL/min/m²) with or without dialysis
* Recent or chronic corticosteroid therapy
* Recent acute coronary syndrome, STEMI type (\< 3 months)
* Urgent surgery or procedure
* Preoperative hemodynamic instability
Primary outcome measure(s)
Procoagulant platelet formation — Throughout the entire study, approximately during 32 months Ex-vivo flow cytometric assessment of the pourcentage of procoagulant platelet population under basal and stimulated conditions.
Trial sites (1)
Facility
City
Region
Status
Cliniques universitaires Saint-Luc
Brussels
Belgium
More Université Catholique de Louvain trials in Belgium
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.